BOCA RATON, Fla., Jan. 26 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) announced today that Thomas E. Rathjen has
been named vice president of investor relations. Mr. Rathjen, a veteran of
Wall Street, brings with him over 20 years of experience to Nabi
Biopharmaceuticals. Most recently, he served as vice president, investor
relations at Genencor International, a Palo Alto-based biotechnology company
that develops and delivers innovative products and services for the healthcare
and bioproducts markets. Prior to this position, Mr. Rathjen held positions
at the New York Stock Exchange (NYSE) and the Nasdaq Stock Market.
At Genencor, Mr. Rathjen was responsible for managing all aspects of its
investor relations program, and successfully repositioned the company to
expand sell-side analytical support and broaden its institutional investor
base. Prior to Genencor, he was vice president at the New York Stock
Exchange, where he opened and managed the Big Board's first office outside of
New York City and had oversight responsibility for all NYSE-listed companies
in 13 western states. Mr. Rathjen was also senior director at the Nasdaq
Stock Market where he maintained the relationships of selected NASDAQ 100
companies with a focus on trading, corporate governance and market-related
issues.
"Tom brings with him extensive experience in investor relations and
securities marketing," stated Thomas H. McLain, chairman, chief executive
officer and president, Nabi Biopharmaceuticals. "He is well respected in the
investment community and his relationships with many notable analyst firms and
investment banks will be instrumental in taking Nabi Biopharmaceuticals'
investor relations program to the next level."
Mr. Rathjen attended Santa Clara University's graduate school of business
and received his B.A. in Political Science from the University of California,
Los Angeles.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering
the immune system to develop and market products that fight serious medical
conditions. We are focusing on developing products addressing commercial
opportunities in our core business areas: Gram-positive bacterial infections,
hepatitis, kidney disease (nephrology), and nicotine addiction. We have three
products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R)
[Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium
(for injection)] and a number of products in various stages of clinical and
pre-clinical development. The company also filed Marketing Authorization
Applications (MAA) in Europe to market Nabi-HB(R) Intravenous [Hepatitis B
Immune Globulin (Human) Intravenous] under the trade name HEBIG(TM) for the
prevention of hepatitis B disease in HBV-positive liver transplant patients;
and for PhosLo, which is already marketed in the United States. The company's
products in development include NicVAX(TM) (Nicotine Conjugate Vaccine), a
vaccine to treat nicotine addiction, and Civacir(TM) [Hepatitis C Immune
Globulin (Human)], an antibody for preventing hepatitis C virus re-infection
in liver transplant patients. For additional information on Nabi
Biopharmaceuticals, please visit our website: http://www.nabi.com .
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
CONTACT:
Thomas E. Rathjen, Vice President, Investor
Relations, +1-561-989-5800
|
